Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study September 3, 2026
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform June 23, 2026
